Vetter And Sentry Biopharma Services Establish Preferred Partnership Agreement
Supports a streamlined path from filling lab to clinic for early-stage study drugs
Said Peter Soelkner, Vetter managing director, "Our partnership with Sentry affirms our mutual commitment to helping clients get highquality products to market quickly and efficiently. It also affirms Vetter's commitment to the North American market." The Chicago facility, which focuses on preclinical to phase II projects, is Vetter's first outside of Germany and is an expansion of Vetter Development Service. It will be operational at the beginning of Q4 2010.
"We're proud to partner with Vetter," said Jennifer Marcum Sentry's chief executive officer. "Both of our companies share the same dedication to the quality and safety of our clients' products." Sentry was recently awarded a contract by The Centers for Disease Control & Prevention (CDC) to store and distribute influenza vaccine for the U.S. National Strategic Reserve. "In addition, we're both privately held companies with central U.S. locations allowing rapid response to industry needs and accessibility to clients across North America."
About Sentry BioPharma Services - www.sentrybps.com
Sentry BioPharma Services maintains cGMP temperaturecontrolled storage, FDA labeling capability, distribution licenses and an active Foreign Trade Zone status to exclusively serve the global pharmaceutical, biotechnology and health care industries. Its facilities, infrastructure and services are specifically designed to meet the warehousing, packaging, logistics and contract service needs of pharmaceutical and biotech firms, health care providers and suppliers, contract research organizations (CROs), contract manufacturing organizations (CMOs), wholesalers, distributors and government entities.
Sentry's management team offers expertise in cold chain storage and logistics, quality assurance, pharmaceutical packaging and kitting development. Sentry also offers strategic solutions for domestic and international transportation and logistics as well as endtoend import and export management. The company's validated processes and inventory tracking systems are FDA compliant, adhere to current Good Manufacturing Practices (cGMPs) and comply with stringent standard operating procedures (SOP) outlined in Sentry's Validation Master Plan. Sentry is VAWD® accredited, which ensures its storage, handling and distribution methods meet the recognized guidelines of the National Association of Board of Pharmacy®. The company is privatelyheld and strategically headquartered in Indianapolis, Ind.
Vetter Pharma International GmbH
Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dualchamber syringe. With about 2,200 employees worldwide, Vetter holds nearly 140 patents and has longstanding experience in handling client products and processes approved by the FDA, the EMA and other authorities. In 2007, the company also received approval as a foreign manufacturer from Japan's Ministry for Health, Labor and Welfare. Vetter received two awards for its facility Ravensburg Vetter South (RVS): The Facility of the Year Award 2007 (Process Innovation category) and the European Outsourcing Award 2007 (Most Improved Process/Plant/Facility category). In February 2010, Vetter won the 2009 Axia award for customer relationship management.
Vetter Development Service provides development support for its pharmaceutical and biotech clients, from preclinical development to regulatory approval and worldwide product launch. Vetter Commercial Manufacturing performs the entire production process, from compounding and aseptic filling to final product packaging. Vetter Solutions' patented drugdelivery systems enable clients to compete more effectively throughout the world.
Press releases you might also be interested in
Weitere Informationen zum Thema "Medizintechnik":
Gluon – KI-Entwicklung leicht gemacht
Die Deep-Learning-Schnittstelle Gluon (Open Source) ermöglicht es Entwicklern, schneller und einfacher Modelle für das Machine oder Deep Learning zu erstellen, ohne dass sich die Trainingsleistung ungebührlich verlängert. Gluon kann mit jeder beliebigen KI-Engine arbeiten.Weiterlesen